Company
United StatesPublic company, NASDAQ: REGNRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN), East Greenbush, NY – FDA Inspections
Inspection records and compliance data for Regeneron Pharmaceuticals, Inc. in East Greenbush, New York. 1 FDA inspection on record, 1 Form 483, last inspected January 16, 2026. Publicly traded as NASDAQ: REGN.
Company Profile
This profile covers Regeneron Pharmaceuticals, Inc. based in East Greenbush, New York, United States.
FDA Inspection History
- FDA inspections
- 1
- OAI
- 0
- VAI
- 0
- NAI
- 0
- Unclassified
- 1
- Form 483s
- 1
- Warning letters
- 0
Inspected January 16, 2026.
FDA inspections (1)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| January 16, 2026 | Not classified | Human Drugs | 1291552 |
FDA documents
Form 483s (1)
Other regulators (1)
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Company Information
Name
Regeneron Pharmaceuticals, Inc.
Stock ticker
REGN
Exchange
NASDAQ
Share price
$951.19
Market cap
$98.4B
Price as of
November 13, 2026
FEI Number
3015581066
Address
350 Tempel Ln, East Greenbush, New York, United States
Country
United States
ID: 6269d8ca-45cd-478d-ab7d-181ccba72353